Background: Humans can be frequently exposed to Bisphenol A (BPA) via multiple sources, and babies are considered to be the most sensitive group to exposure of BPA. Aims: To investigate the inhibition potential of BPA towards human liver microsomes (HLMs)-catalyzed zidovudine (AZT) glucuronidation.
Introduction
Endocrine disrupting chemicals (EDCs) are natural and man-made chemicals acting via mimicking or blocking natural hormone functions in the body 1 . EDCs can exhibit significant influence towards various hormonal systems, such as estrogen, androgen, progestagen, corticosteroid and thyroid signaling systems 1 . Bisphenol A (BPA) has been widely used as monomer for the production of polycarbonate and a precursor of epoxy resins 2 . Human can be frequently exposed to BPA via multiple sources, and babies are considered to be the most sensitive group to exposure of BPA 3 . For example, babies that are not breast-fed, might drink powdered or liquid milk formula, and the cans of milk formula might release BPA into milk formula. BPA is a well-known EDC, and the exposure Corresponding author: Yuan-Qing Yao Gynecologic surgical department The General Hospital of Chinese People's Liberation Army, China. E-mail: yaoyuanqing123456@163.com of BPA has been closely correlated with a variety of diseases, including cardiovascular disease and diabetes 4, 5 . Additionally, the increased exposure of BPA is closely correlated with increased inflammation and oxidative stress 6 . Drug-metabolizingenzymes-catalyzed biotransformation process is one of the most important elimination pathways. BPA has been demonstrated to mainly undergo UDP-glucuronosyltransferases (UGTs) catalyzed glucuronidation reaction, and UGT2B15 was demonstrated to be the major UGT isoform 7, 8 , indicating the good interaction between BPA and UGT2B isoforms. Given that UGT2B isoforms are involved in the metabolic elimination of many clinical drugs, the potential influence of BPA administration towards the drug metabolism was speculated. Zidovudine (AZT), the first U.S. government approved drug for antiretroviral treatment (ART), has been clinically used and prescribed under the name Retrovir. AZT has a narrow therapeutic index, and is mainly metabolized through UGT2B isoforms-catalyzed biotransformation reaction 9 . In the present study, the inhibition capability of BPA towards the typical substrate of UGT2B zidovudine (AZT) was 
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Materials and Methods
Chemicals and reagents
Bisphenol A (purity≥99%), 3'-azido-3'-deoxythimidine (AZT), Tris-HCl, alamethicin and uridine 5'-diphosphoglucuronic acid (UDPGA) (trisodium salt) were obtained from Sigma-Aldrich (St Louis, MO). Mixed pooled human liver microsomes (HLMs) from 25 donors were purchased from Research Institute for Liver Diseases (RILD, Shang Hai, China).
AZT glucuronidation assays and analysis method 500 μM of AZT was used to incubate in the human liver microsomal incubation system (0.5 mg/ml of HLM, 5 mM UDPGA, 5 mM MgCl 2 , 50 mM Tris-HCl buffer (pH 7.4), 50 μg/mg protein alamethicin). The incubation time was 20 min, and the analysis of AZT glucuronidation was performed on HPLC system. The HPLC column was eluted at 1 ml/min with a mobile phase of acetonitrile:aqueous containing 0.2% formic acid (v:v=12:88). The detection wavelength was set at 267 nm. The standard curve of AZT was employed to quantify the AZT metabolite due to the lack of the standard of AZT glucuronide.
Determination of BPA's inhibition towards the glucuronidation reaction of AZT
Inhibition ability of different concentrations of BPA towards the glucuronidation of AZT was determined, and the IC 50 value was determined as previously described 10 . The reaction velocity was determined at multiple concentrations of BPA and AZT. Dixon plot (1/reaction velocity versus the concentration of BPA) and Lineweaver-Burk plot (1/reaction velocity versus 1/[the concentration of AZT]) were employed to determine the inhibition kinetic type, and nonlinear regression equation was performed using the equations for competitive inhibition (1), noncompetitive inhibition (2).
V=Vmax*[S]/(Km/(1+([I]/Ki))+[S]) (1) V=Vmax*[S]/(Km+[S])*(1+([I]/Ki)) (2)
Where the items are defined as followed: V is the reaction velocity, [S] and [I] are the concentrations of substrate and inhibitor, respectively. Km value is the substrate concentration in which the velocity reached to half of the maximum velocity (Vmax) of the reaction. Ki value is the inhibition constant.
Results
The concentration-dependent inhibition behaviour of BPA towards human liver microsomes (HLMs)-catalyzed AZT glucuronidation was firstly investigated using multiple concentrations of BPA. The results (Fig.  1) showed that the activity of AZT glucuronidation was inhibited by -7.6%, -10.9%, -16.4%, -7.9%, -5.1%, -2.1%, 19.1%, 33.7%, and 50% by 0.1, 0.5, 1, 5, 10, 20, 40, 80, and 100 μM of BPA. Dixon plot ( Fig. 2A) and Lineweaver-Burk plot (Fig. 2B ) have been regarded to be the most common methods to determine the inhibition type. of duplicate experiment. Fig. 3 and parameter (K i )
The intersection point was located in the second quadrant and verticle axis in the Dixon and LineweaverBurk plot, respectively. The inhibition kinetic parameter (K i ) was calculated to be 3.2 μM through the data fitting with competitive inhibition equation (Fig. 3) .
Discussion
Humans will be exposed to numerous xenobiotics everyday, such as food, drugs, herbs, and environmental pollutants. Therefore, the interaction among the compounds existed in these substances will occur, including drug-drug interaction and herb-drug interaction. All these interactions are mainly induced through affecting the pharmacokinetic behaviour, especially for the influence towards the metabolism of compounds. Many great efforts have been given to cytochrome P450 (CYP) which has been the most important DME involved in the metabolism of most of clinical drugs, and many compounds have been demonstrated to inhibit the activity of CYP isoforms. For example, the potential anti-tumor drug noscapine can inhibit the activity of CYP3A4 and CYP2C9 to explain the clinical noscapine-warfarin interaction
11
. The herbal components ginsenosides have been reported to exhibit inhibition towards the activity of several CYP In the present study, we tried to investigate the inhibition of HLMs-catalyzed AZT glucuronidation by BPA which is an important endocrine disrupting chemical. Possible BPA-AZT interaction was indicated due to the competitive inhibition of BPA towards the glucuronidation of AZT with relatively low K i value. Additionally, some previous literatures have indicated that the addition of bovine serum albumin (BSA) in the incubation system mgiht significantly influence the in vitro inhibition parameters 17 . Therefore, different
